Skyhawk's proprietary platform revolutionizes disease treatment by developing small molecule therapeutics that modify RNA expression
April 13, 2021
Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President and Graeme Smith PhD as SVP NonClinical Development
Elliot Ehrich MD brings 25+ years R&D and clinical development leadership experience to the company; Graeme Smith PhD DABT brings 15+ years of nonclinical drug development leadership experience to the company.
A busy, buzzy Vertex finds a high-profile partner in the RNA-drugging world to launch a fresh discovery effort
As Vertex began zeroing in on launching its big combo for cystic fibrosis, the oft-lauded biotech started to selectively snap up new technologies that promised to break the therapeutic mold on the way some diseases are treated.
